Sandbox:Preeti: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ||
! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Mechanism | ! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Mechanism | ||
! colspan=" | ! colspan="10" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestations | ||
! colspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ! colspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ||
Line 18: | Line 18: | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ||
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | ! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | ||
! colspan=" | ! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs | ||
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC | ! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS | ||
Line 34: | Line 34: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |V/S | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |V/S | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ||
Line 41: | Line 40: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ||
|- | |- | ||
! colspan=" | ! colspan="26" align="left" style="background:#4479BA; color: #FFFFFF;" + |HL | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 70: | Line 68: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan=" | ! colspan="26" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ||
Line 76: | Line 74: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Precursor B-cell Lymphoma | * Precursor B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 105: | Line 102: | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
* Reciprocal translocation t(14;18)(q32;q21) | * Reciprocal translocation t(14;18)(q32;q21) | ||
* Overexpression of ''BCL2'' | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Second most common subtype of NHL | * Second most common subtype of NHL | ||
*Whites>>African-americans or Asians | |||
*Median age at diagnosis of 65 years | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Slightly positive family history | |||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
*[[Fever]] | *[[Fever]] | ||
Line 119: | Line 121: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Painless | * Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 161: | Line 161: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Palpable masses in skin, breast, and salivary glands | * Palpable masses in skin, breast, and salivary glands | ||
* Generalized lymphadenopathy | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 205: | Line 205: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Painless rapidly enlarging [[lymph nodes]] | * Painless rapidly enlarging [[lymph nodes]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 243: | Line 242: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |V/S | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |V/S | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ||
Line 278: | Line 276: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* [[Swollen lymph nodes]] in the neck, axilla, or groin | |||
* Jaw mass | * Jaw mass | ||
* [[Abdominal mass|Abdominal masses]] | * [[Abdominal mass|Abdominal masses]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 310: | Line 308: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 339: | Line 336: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 370: | Line 366: | ||
** Deletion 7q21-32 | ** Deletion 7q21-32 | ||
** Translocations of the CDK6 gene located on 7q21 | ** Translocations of the CDK6 gene located on 7q21 | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 411: | Line 406: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 442: | Line 436: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 494: | Line 487: | ||
* [[Petechiae]] | * [[Petechiae]] | ||
* [[Splenomegaly]] | * [[Splenomegaly]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 529: | Line 521: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Precursor T-cell Lymphomas | * Precursor T-cell Lymphomas | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 556: | Line 547: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 583: | Line 573: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 634: | Line 623: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cutaneous manifestations | * Cutaneous manifestations | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 651: | Line 639: | ||
! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma | ! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma | ||
! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 678: | Line 665: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 705: | Line 691: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 732: | Line 717: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type | ! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 759: | Line 743: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 786: | Line 769: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified | ! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 19:13, 7 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Category | Disease | Etiology | Mechanism | Clinical manifestations | Paraclinical findings | Gold standard | Associated findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab findings | |||||||||||||||||||||||||
Demography | History | Symptoms | Signs | CBC | PBS | PT/PTT | Immunochemistry | Histopathology | Other | ||||||||||||||||
Inherited | Acquired | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | Hepatosplenomegaly | Other | WBC | Hb | Plt | |||||||||||||
HL | |||||||||||||||||||||||||
Hodgkin's Lymphoma | |||||||||||||||||||||||||
NHL | |||||||||||||||||||||||||
B Cell Lymphoma | Precursor B-cell lymphoblastic leukemia/lymphoma |
|
|||||||||||||||||||||||
Follicular lymphoma |
|
|
|
+ | + |
|
+ |
| |||||||||||||||||
Mantle cell lymphoma |
|
|
Abdominal distention |
|
+ |
|
|
↓ | Nl to ↓ |
|
|
Elevated LDH | |||||||||||||
Diffuse large B cell lymphoma |
|
|
|
↓ | ↓ | Nl to ↓ |
|
Centroblastic
Immunoblastic
Anaplastic
|
|
||||||||||||||||
Category | Disease | Etiology | Inherited | Acquired | Demography | History | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | Hepatosplenomegaly | Other | WBC | Hb | Plt | PBS | PT/PTT | Immunochemistry | Histopathology | Other lab findings | Gold standard | Associated findings | |
Burkitt lymphoma |
|
|
|
|
|||||||||||||||||||||
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma |
|
||||||||||||||||||||||||
Marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type |
|
|||||||||||||||||||||||
Splenic marginal zone lymphoma |
|
|
|||||||||||||||||||||||
Nodal marginal zone B-cell lymphoma |
|
+ |
|
|
|
| |||||||||||||||||||
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) |
|
||||||||||||||||||||||||
Hairy cell leukemia |
|
|
|
||||||||||||||||||||||
Precursor T-cell lymphoblastic leukemia/lymphoma |
|
||||||||||||||||||||||||
Adult T cell leukemia/lymphoma | |||||||||||||||||||||||||
T cell lymphoma | Anaplastic large cell lymphoma | ||||||||||||||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
|||||||||||||||||||||
Peripheral T-cell lymphoma | Subcutaneous panniculitis-like T-cell lymphoma | ||||||||||||||||||||||||
Hepatosplenic gamma-delta T-cell lymphoma | |||||||||||||||||||||||||
Enteropathy-type intestinal T-cell lymphoma | |||||||||||||||||||||||||
Extranodal T-cell lymphoma, nasal type | |||||||||||||||||||||||||
Angioimmunoblastic T-cell lymphoma | |||||||||||||||||||||||||
Peripheral T-cell lymphoma, unspecified |